Intraven Pharmaceuticals And Automobiles Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-12-2024
- Paid Up Capital ₹ 0.41 M
as on 21-12-2024
- Company Age 52 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2019)
- Profit -252.89%
(FY 2019)
- Ebitda -276.58%
(FY 2019)
- Net Worth -8.00%
(FY 2019)
- Total Assets 5.23%
(FY 2019)
About Intraven Pharmaceuticals And Automobiles
The Corporate was formerly known as Intraven Pharmaceuticals Private Limited. The Company is engaged in the Automotive Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.41 M, as per Ministry of Corporate Affairs (MCA) records.
Lakshmi Vallurupalli and Varun Vallurupalli serve as directors at the Company.
- CIN/LLPIN
U24230TG1972PTC001498
- Company No.
001498
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Apr 1972
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- LocationAndhra Pradesh, Telangana
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Intraven Pharmaceuticals And Automobiles?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lakshmi Vallurupalli  | Director | 01-Aug-1997 | Current |
| Varun Vallurupalli | Director | 20-Feb-2019 | Current |
Financial Performance of Intraven Pharmaceuticals And Automobiles.
Intraven Pharmaceuticals And Automobiles Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 252.89% decrease in profit. The company's net worth dipped by a decrease of 8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Intraven Pharmaceuticals And Automobiles?
In 2020, Intraven Pharmaceuticals And Automobiles had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Varun International Convention Center Private LimitedActive 5 years 9 monthsVarun Vallurupalli is a mutual person
Varun Hospitality Private LimitedActive 41 years 5 monthsLakshmi Vallurupalli and Varun Vallurupalli are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Intraven Pharmaceuticals And Automobiles?
Unlock and access historical data on people associated with Intraven Pharmaceuticals And Automobiles, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Intraven Pharmaceuticals And Automobiles, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Intraven Pharmaceuticals And Automobiles's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
